December 15, 2014
Sumitomo Dainippon Pharma announced on December 12 that its investigational attention deficit hyperactivity disorder (ADHD) treatment dasotraline (development code: SEP-225289) significantly improved the symptoms of ADHD in adult patients in comparison with placebo in a PII study conducted in the...read more